Anavex Life Sciences Corp (AVXL)

[bb8675309]

AVXL should have a minimum of $3.0 Billion MC imo.

Because it is cutting edge in the CNS Biotech space winning like no other current company. Company Current Value is $15 Billion. imo.

AVXL has proven drug trial results in Phase 3 AVATAR meeting primary and secondary endpoints. Worth $ 1.5 Billion.

ANAVEX®2-73: A POTENTIAL BLOCKBUSTER DRUG IN THE MAKING!

AVXL - Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Improved both Primary Cognitive and Secondary MDS-UPDRS Efficacy Endpoints with Significant Biomarker Correlation in Placebo-Controlled Phase 2 Clinical Trial for the Treatment of Patients with Parkinson’s Disease Dementia. Worth $1.5 to 5 Billion. Conservative.

https://www.anavex.com/post/anavex-2-73-blarcamesine-avatar-phase-3-trial-met-primary-and-secondary-efficacy-endpoints

https://www.anavex.com/press-releases/anavex-life-sciences-announces-anavex%C2%AE2-73-(blarcamesine)-improved-both-primary-cognitive-and-secondary-mds-updrs-efficacy-endpoints-with-significant-biomarker-correlation-in-placebo-controlled-phase-2-clinical-trial-for-the-treatment-of-patients-with-parkinson%E2%80%99s-disease-dementia

https://www.aviseanalytics.com/anavex2-73-a-potential-blockbuster-drug-in-the-making/